



## Development of the vertebral morphogenetic field in the mouse: Interactions between Crossveinless-2 and Twisted Gastrulation

Lise Zakin, Carrie A. Metzinger, Ellen Y. Chang, Catherine Coffinier, E.M. De Robertis\*

Howard Hughes Medical Institute and Department of Biological Chemistry, University of California, Los Angeles, CA 90095-1662, USA

### ARTICLE INFO

#### Article history:

Received for publication 20 December 2007

Revised 15 August 2008

Accepted 18 August 2008

Available online 29 August 2008

#### Keywords:

BMP

Crossveinless-2

Chordin

Twisted Gastrulation

Tolloid

Vertebra

Morphogenetic field

Cartilage

Pattern formation

### ABSTRACT

Crossveinless-2 (Cv2), Twisted Gastrulation (Tsg) and Chordin (Chd) are components of an extracellular biochemical pathway that regulates Bone Morphogenetic Protein (BMP) activity during dorso-ventral patterning of *Drosophila* and *Xenopus* embryos, the formation of the fly wing, and mouse skeletogenesis. Because the nature of their genetic interactions remained untested in the mouse, we generated a null allele for Cv2 which was crossed to Tsg and Chd mutants to obtain Cv2; Tsg and Cv2; Chd compound mutants. We found that Cv2 is essential for skeletogenesis as its mutation caused the loss of multiple bone structures and posterior homeotic transformation of the last thoracic vertebra. During early vertebral development, Smad1 phosphorylation in the intervertebral region was decreased in the Cv2 mutant, even though CV2 protein is normally located in the future vertebral bodies. Because Cv2 mutation affects BMP signaling at a distance, this suggested that CV2 is involved in the localization of the BMP morphogenetic signal. Cv2 and Chd mutations did not interact significantly. However, mutation of Tsg was epistatic to all CV2 phenotypes. We propose a model in which CV2 and Tsg participate in the generation of a BMP signaling morphogenetic field during vertebral formation in which CV2 serves to concentrate diffusible Tsg/BMP4 complexes in the vertebral body cartilage.

© 2008 Elsevier Inc. All rights reserved.

### Introduction

Pattern formation in the developing embryo is controlled by gradients of morphogens in which localization, local concentration, and binding to receptors must be precisely regulated. Extracellular protein–protein interactions ultimately determine how much signal is sensed by a cell at a specific position and its behavioral response within a morphogenetic field. The Bone Morphogenetic Protein (BMP) family of morphogens is involved in many developmental processes ranging from dorso-ventral patterning (De Robertis and Kuroda, 2004; Little and Mullins, 2006) to organogenesis and skeletal development (Hogan, 1996; Massague and Chen, 2000; Zhao et al., 2002). Central to the establishment of BMP morphogenetic gradients are the secreted BMP-binding proteins Chordin (Chd), Chordin-like-1 (Chdl-1), Chordin-like-2 (Chdl-2), Noggin, Twisted Gastrulation (Tsg) and Crossveinless-2 (CV2). Chd, Tsg and CV2 have been reported to function both as pro- and anti-BMPs depending on the model system studied (Little and Mullins, 2006; Oelgeschlager et al., 2000; Scott et al., 2001; Eldar et al., 2002; Nosaka et al., 2003; Coles et al., 2004; Petryk et al., 2004; Zakin and De Robertis, 2004; Ikeya et al., 2006; O'Connor et al., 2006; Zhang et al., 2007). Chdl-1 (Coffinier et al., 2001; Nakayama et al., 2001) and Chdl-2

(Nakayama et al., 2004; Zhang et al., 2007) are molecules that function as BMP antagonists in combination with Tsg, behaving similarly to Chd. The Chordin system is regulated by the Tolloid family of metalloproteinases that inactivate Chd by proteolytic cleavage and release previously inactive BMPs, which are then able to signal (Piccolo et al., 1997; Larrain et al., 2001).

Cv2 was first identified in *Drosophila* as a gene required for the formation of the wing crossveins, structures that require high BMP signaling (Conley et al., 2000; O'Connor et al., 2006; Blair, 2007). Mouse CV2 contains 5 cysteine-rich (CR) domains (also found in Chd, which function as BMP-binding modules) (De Robertis and Kuroda, 2004), a partial Von Willebrand Factor-D domain (vWFD), a trypsin inhibitor-like (TIL) domain involved in protein–protein interactions and/or oligomerization (Coffinier et al., 2001), and a heparin/extracellular matrix binding site within the vWFD domain that is thought to limit CV2 diffusion (Rentzsch et al., 2006; Serpe et al., 2008). The amino terminal domain of CV2 binds BMP, blocking the sites that are recognized by BMP receptors type I and II, thus preventing signaling (Zhang et al., 2008). One difference with Chd is that the Cv2 gene product is constitutively secreted as two disulfide-linked fragments generated by an auto-catalytic cleavage occurring in the secretory pathway (Binnerts et al., 2004; Serpe et al., 2008; Ambrosio et al., 2008). Unlike Chd, vertebrate CV2 is completely resistant to digestion by Tolloid metalloproteinases (Ambrosio et al., 2008).

\* Corresponding author. Fax: +1 310 206 2008.

E-mail address: [ederobertis@mednet.ucla.edu](mailto:ederobertis@mednet.ucla.edu) (E.M. De Robertis).

Both pro- and anti-BMP effects of CV2 have been reported depending on the experimental situation. Anti-BMP effects were described *in vitro* during the differentiation of endothelial cells (Moser et al., 2003), osteoblasts and chondrocytes (Binnerts et al., 2004). However, the co-transfection of Cv2, *Smad1* and *Bmp4* in Cos7 cells revealed a pro-BMP activity (Kamimura et al., 2004). The electroporation of Cv2 in the neural tube of chick embryos produced pro-BMP phenotypes (Coles et al., 2004). In the mouse, Cv2 has been reported to function as a pro-*Bmp4* in developing embryos (Ikeya et al., 2006). Likewise, pro-BMP effects were described in zebrafish embryos in morpholino knock-down experiments (Rentzsch et al., 2006; Moser et al., 2007). However, potent anti-BMP effects for CV2 were demonstrated in biochemical studies and in *Xenopus* and zebrafish overexpression experiments (Coles et al., 2004; Rentzsch et al., 2006; Zhang et al., 2007). In *Xenopus*, depletion of CV2 with morpholinos increased BMP signaling and strongly synergized with the depletion of the BMP antagonist *Chd*, indicating that the overall function of CV2 in early development is to inhibit BMP signaling (Ambrosio et al., 2008). Like *Chd*, CV2 binds directly to Tsg protein, which greatly increases its BMP inhibitory activity (Ambrosio et al., 2008).

In the fly wing, CV2 functions as a co-factor for Dpp/BMP that may concentrate the activity of this ligand in the crossvein. First, Dpp/Gbb BMP ligands form a diffusible complex with Sog/Chd and the dTsg-2/Cv-1 protein (Vilmos et al., 2005; Shimmi et al., 2005), and are subsequently released at the crossvein for signaling after cleavage of Sog by the Tollid-related metalloproteinase Tlr (Ralston and Blair, 2005; Blair, 2007). Recent work by Serpe et al. (2008) has shown that CV2 also acts as a co-receptor that binds to Thickveins (Tkv, a Type I BMP receptor), facilitating BMP signaling at intermediate CV2 concentrations and inhibiting signaling at high CV2 concentrations. In the *Drosophila* wing, the CV2 secreted protein binds to the glypican Dally and stays locally, not signaling beyond one or two cell diameters from its site of synthesis (Serpe et al., 2008).

In the *Xenopus* gastrula, CV2 is expressed in the ventral (high-BMP) center. Biochemical studies have shown that mouse CV2 binds with high affinity (1 nM) to Chd protein, and even more strongly to Chd/BMP complexes or to Chd fragments resulting from cleavage of Chd by tolloids (Ambrosio et al., 2008). This led to the proposal that the pro-BMP effects of CV2 are caused by directing the flow of Tsg/Chd/BMP complexes towards more ventral regions in which CV2 is tethered to the cell surface (Ambrosio et al., 2008; Bier, 2008). The flow of BMP4 from dorsal toward ventral regions has been observed directly in the *Xenopus* gastrula, and shown to require endogenous Chd (Ben-Zvi et al., 2008). We now propose that a similar flow of Tsg/Chd/BMP4 toward prevertebral cartilage regions expressing CV2 protein at their surface might explain the formation of a BMP morphogenetic gradient during mammalian vertebral development.

In the present study we investigated the role of Cv2 during mouse embryogenesis and its interactions with *Chd* and *Tsg* in controlling BMP signaling using mouse loss-of-function mutations. To analyze Cv2 function *in vivo*, we inactivated the Cv2 gene, characterized the mutant phenotype, and crossed heterozygous mice with the *Chd* (Bachiller et al., 2003) and *Tsg* (Zakin and De Robertis, 2004) mutant strains to generate compound Cv2; *Chd* and Cv2; *Tsg* mutants. We found that Cv2<sup>-/-</sup> pups died at birth (in agreement with Ikeya et al., 2006), of respiratory failure and displayed multiple skeletal abnormalities. Little or no interaction between Cv2 and *Chd* was observed. Surprisingly, the Cv2<sup>-/-</sup> lethality and skeletal phenotype were completely suppressed in Cv2<sup>-/-</sup>; *Tsg*<sup>-/-</sup> double mutants. This rescue indicated that *Tsg* is epistatic over Cv2. The results also indicate that *Tsg*, Cv2, and possibly other BMP- and Tsg-binding proteins (such as Chd1-1, Chd1-2 and Chd), interact during skeletal development. We propose that the function of CV2 is to generate and maintain a BMP activity gradient in the developing vertebral morphogenetic field.

## Materials and methods

### Generation of Cv2 mutant mice

Genomic DNA for Cv2 recombination arms was isolated from a 129/SVJ mouse BAC library (Incyte Genomics) and subcloned into the pGN vector (Supplementary Fig. 1A) (Le Mouellic et al., 1990). The plasmid was electroporated into 129/SVJ ES cells and stable transfection was achieved after G418 selection. Clones were screened for homologous recombination by PCR using the following primers, CV2-5'2 (5'TCC ACC TTC TCA TTC ACA AC3') and CV2-3'2 (5'CGG GCC TCT TCG CTA TTA CG3') which yielded a diagnostic band of 2530 bp and homologous recombination was confirmed by Southern Blot (Supplementary Fig. 1B). The Cv2 mutant strain was backcrossed into the hybrid strain B6SJL/F1/J (Jackson Laboratories). The *Tsg* and *Chd* mutant strains were previously described (Bachiller et al., 2003; Zakin and De Robertis, 2004) and maintained in the same genetic background. The Cv2, *Tsg* and *Chd* mutant mouse strains used in this work are publicly available from Jackson Laboratories through an agreement made possible by the Howard Hughes Medical Institute (<http://jaxmice.jax.org>, stock numbers are 007552 for *Chd*, 007553 for *Tsg* and 007554 for Cv2).

### Genotyping and RT-PCR

Genotyping of the Cv2 mutant strain was performed by PCR (Supplementary Fig. 1A) using the following primers: pGN1 (5'ACC CTC TGT GTC CTC CTG TTA A3'), Cv2down (5'AGT CTC CTC CTA TGT TTC TTG C3') and Cv2up (5'TCT CTT TGG TGA TGC TAT TGT T3'). *Tsg*22 (5'AGC CTG AAT GTT TGA ATG TTT A3'), *Tsg*23 (5'CCT GAA TCC TTA CCT GAA TGA G 3') and *LacZ*3 (5'TCT GCC AGT TTG AGG GGA CGA C3') were used to genotype the *Tsg* mutant strain as previously described (Zakin and De Robertis, 2004) and *Neo*2 (5'GTT CCA CAT ACA CTT CAT TCT CAG3'), *Null Low* (5'GGT AGG AGA CAG AGA AGC GTA AAC T3') and *Null Up2* (5'GAG TTA GGA GGT GGA GCT CTA CAC T3') for the *Chd* mutant strain (Bachiller et al., 2000).


For measuring transcripts by RT-PCR, the primers were RTCv2up (5'CTC CTT CCT GAC AGG GTC TG3') and RTCv2down (5'GGG TAC AAC CTT TGC ATC GT3') for Cv2, RTLacZdown (5'TTG AAA ATG GTC TGC TGC TG3') and RTLacZup (5'TAT TGG CTT CAT CCA CCA CA3') for *LacZ*, and HPRTFforward (5'CAC AGG ACT AGA ACA CCT GC3') and HPRTreverse (5'GCT GGT GAA AAG GAC CTC T3') for HPRT. They yielded bands of 295 bp, 234 bp and 249 bp respectively.

### *In situ* hybridization, histology, immunohistochemistry and skeletal preparations

Procedures for *in situ* hybridization on whole-mount and cryostat sections were as described (<http://www.hhmi.ucla.edu/derobertis/>) using the following probes: Cv2 (Coffinier et al., 2002), *Tsg* (Zakin and De Robertis, 2004), *Chd* (Bachiller et al., 2000), *Chd1-1* (previously designated as *Neuralin 1*, Coffinier et al., 2001), *Chd1-2* (Genbank accession number AF 338222), and *Bmp1/Tll1* (Scott et al., 1999). Alcian Blue/Alizarin Red skeletal preparations,  $\beta$ -galactosidase, Hematoxylin and Eosin (H&E) and Mallory's tetrachrome stainings were as described (Zakin and De Robertis, 2004). For antibody staining, embryos were fixed in 4% paraformaldehyde in PBS, dehydrated, embedded in paraffin, serially sectioned at 7  $\mu$ m and sections processed as described (<http://www.hhmi.ucla.edu/derobertis/>). Rabbit anti-pSmad1 (Cell Signaling #9511L) and anti-CV2 (R and D AF2299) antibodies were used at a 1:100 dilution.

### Preparation of mouse embryonic fibroblasts (MEFs)

MEFs were prepared as previously described (Hogan et al., 1994), with the following modifications. 12.5 days post coitum (d.p.c.)



**Fig. 1.** CV2 expression pattern at 12.5 d.p.c. and *Cv2*<sup>-/-</sup> phenotype. (A–A') Detection of the CV2 protein on sagittal paraffin sections of wild-type and *Cv2* mutant mouse embryos at 12.5 d.p.c. by immunohistochemistry. Note in wild-type the CV2 protein staining in the vertebral bodies (vb). No CV2 protein is detected in *Cv2*<sup>-/-</sup> embryos. Asterisks indicate unspecific signals present in both wild-type and mutant embryos. bo, basioccipital bone. (B) Higher magnification view of the CV2 staining in the vertebral bodies. ivd, intervertebral disc. (B') The CV2 signal in thyroid cartilages (tc) and tracheal rings (tr), shown at a higher magnification. (C–C') External view of littermates from *Cv2*<sup>-/-</sup> intercrosses showing shorter tails in *Cv2*<sup>-/-</sup> compared to wild-type and exencephaly observed in 25% of the mutants. Inset shows a *Cv2*<sup>-/-</sup> mutant lacking exencephaly. (D–E') Mallory's tetrachrome staining of sagittal paraffin sections of wild-type (top panels) and mutant (bottom panels) neonates. *Cv2*<sup>-/-</sup> embryos die at birth of respiratory failure. Note in the thoracic region of *Cv2*<sup>-/-</sup> the reduction of the lumen of the trachea and the decreased distance between the vertebral column and the manubrium of the sternum (ms). Insets show tracheas of wild-type and *Cv2*<sup>-/-</sup> embryos stained with Alcian Blue and Alizarin Red. Note that in the mutant the cartilage rings that support the trachea are absent. Boxed areas are shown at higher magnification in (E) and (E'). In the mutant the collapse of the tracheal lumen (Lt) is due to the absence of the tracheal rings (tr). CNS, central nervous system; cr, cricoid cartilage; h, hyoid bone; li, liver; m, muscle; th, thyroid cartilage; to, tongue.

embryos were isolated from heterozygous mouse intercrosses. After head and viscera were removed, individual embryos were minced on a petri dish, using a sterile razor blade. 5 ml of trypsin (0.05%) was added to the minced tissue, transferred to a 15 ml falcon tube and incubated in 5% CO<sub>2</sub> at 37 °C for 20 min. Trypsin was subsequently inactivated with 10 ml of DMEM/10% fetal calf serum (FCS). Cells from a single embryo were plated on a 10 cm tissue culture dish in DMEM/10% FCS.

#### Western blot analyses


Tissue or cell extracts were prepared in RIPA lysis buffer with a cocktail of phosphatase inhibitors (Complete-EDTA free from Roche and phosphatase inhibitor cocktail sets I and II from Calbiochem). Total-ERK (1:1000 dilution, Cell Signaling #9102),  $\alpha$ -tubulin (1:1000, Calbiochem #CP06) and pSmad1 (1:1000 dilution, Cell Signaling #9511L) antibodies were used for western blot analyses. Quantitative analyses of the western blots in Fig. 7 and Supplementary Fig. 3 were performed with the Li-Cor Odyssey infrared imager using anti-mouse IRdye 680 (Li-Cor # 926-32220) and anti-rabbit IRdye 800 (Li-Cor # 926-32211) secondary antibodies at a dilution of 1:1500.

## Results

### *Disruption of the Cv2 locus results in neonatal death and skeletal abnormalities*

To investigate the role of *Cv2* *in vivo* we generated a mutant allele of the mouse gene by inserting the reporter gene *LacZ* in frame at the initiation codon and deleting sequences between exon 1 and intron 2 (Supplementary Fig. 1). Loss of CV2 protein expression was confirmed by the absence of CV2 protein in prevertebral cartilages (compare Figs. 1A and A') and loss of *Cv2* transcript by RT-PCR on MEFs (Supplementary Fig. 1D). The *LacZ* reporter recapitulated the expression of endogenous *Cv2* in the tail bud, dorsal neural tube and brain dorsal midline at 8.5–9.5 d.p.c. and in the branchial arches and heart at 9.5 d.p.c. (compare in Supplementary Fig. 1 panels E to E' and F to F').


*Cv2*<sup>-/-</sup> pups died at birth of respiratory failure. They displayed major skeletal abnormalities and shorter tails in all cases, and exencephaly with 25% penetrance (Figs. 1C–E' and Supplementary Fig. 2). The skeletal phenotypes were in agreement with the expression of CV2 protein in differentiating cartilage, such as the vertebral bodies and trachea (Figs. 1A, B and B'). The expression of *Cv2*



**Fig. 2.** Pattern of expression of genes containing BMP-binding CR modules in the mouse vertebral column. (A–D') *Cv2* is expressed in a pattern complementary to that of *Tsg*, *Chd1* and *Chd* in the vertebral column of 12.5 d.p.c. embryos. *In situ* hybridization on cryostat sections. Boxed areas in A, B, C, D are shown at higher power in A', B', C', D', respectively. *Cv2* mRNA is expressed in the vertebral body (vb) (A, A') while *Tsg* (B, B'), *Chd1* (C, C') and *Chd* (D, D') all co-localize in the intervertebral disc (ivd).

in the brain dorsal midline (Supplementary Figs. 1E, E') correlated with the exencephaly phenotype. *Cv2*<sup>-/-</sup> mutants presented a dramatic reduction in the size of the vertebral bodies as well as neural arches of the vertebral column (Supplementary Figs. 2A, A', C–D'). The 13th


thoracic vertebra displayed a posterior homeotic transformation characterized by the loss of the 13th rib with an almost complete penetrance (Supplementary Figs. 2C, C'). In the skull, a defective fusion of the basisphenoid bone and reduced ossification of the tympanic



**Fig. 3.** Smad1 phosphorylation in the developing pre-vertebral region of *Cv2*<sup>-/-</sup> 12.5 d.p.c. embryos (posterior, more immature regions are shown). Sagittal paraffin sections of wild-type (A, C, E, G, I) and *Cv2*<sup>-/-</sup> (B, D, F, H) 12.5 d.p.c. embryos. (A, B) Sections stained with H&E. Boxed areas are shown at higher magnification below. (C–F) H&E staining revealed no morphological differences between wild-type and mutant embryos in this posterior region. cm, condensed mesenchyme (prospective intervertebral disc); um, uncondensed (intervertebral) mesenchyme (prospective vertebral body). (G, H) Detection of phosphorylated Smad1 (pSmad1) by immunohistochemistry. pSmad1 was detected at higher levels in the condensed (intervertebral) mesenchyme (indicated by brackets in G); however, this signal was lost in the mutant (brackets in H). (I) Detection of CV2 protein by immunohistochemistry in sections counterstained with H&E. Note that the localization of the CV2 protein in the uncondensed mesenchyme (future vertebral body) is complementary to the pSmad1 domain at this stage. (J) Summary of the expression of CV2 protein compared to *Bmp*, *Tsg*, *Chd*, *Chd1-1*, *Chd1-2* and *Tolloid* mRNAs and to pSmad1 levels in the posterior vertebral column. The highest levels of pSmad1 overlap with *Bmp*, *Tsg*, *Chd*, *Chd1-1*, *Chd1-2* and *Tolloid* in the cm (future intervertebral region), and are complementary to the domain of CV2 expression in the um (prospective vertebral body). n, notochord.

ring were present (Supplementary Figs. 2B, B'). Many of these bone phenotypes confirm those previously reported by the group of Yoshiki Sasaki (Ikeya et al., 2006). We propose that respiratory failure is the

most probable cause of the lethality, since the lumen of the trachea (Lt) was almost inexistent, compressed between the vertebral column and the manubrium sterni (Figs. 1E–E'). This phenotype was caused by



**Fig. 4.** Impaired vertebral body differentiation in *Cv2*<sup>-/-</sup> 12.5 d.p.c. embryos (anterior, more mature vertebral regions are shown). Sagittal paraffin sections of wild-type (A, C, E, G, I) and *Cv2*<sup>-/-</sup> (B, D, F, H) 12.5 d.p.c. embryos. (A, B) Sections stained with H&E. Boxed areas are shown at higher power in (C, D and E, F). Vertebral bodies (vb) are smaller in the mutant, while the intervertebral discs (ivd) appear to be unaffected. n, notochord. (G, H) pSmad1 is detected at higher levels in the vb at this stage. In *Cv2*<sup>-/-</sup> mutants the area stained for pSmad1 (brackets) is smaller than in the wild-type, reflecting the reduced size of the vertebral body. (I) Detection of CV2 protein by immunohistochemistry in sections counterstained with H&E. CV2 is present in the vb, co-localizing with pSmad1. (J) Summary of the expression of CV2 protein compared to that of *Bmp*, *Tsg*, *Chd*, *Chd1-1*, *Chd1-2* and *Tolloid* mRNAs and to pSmad1 levels in the anterior vertebral column. At this stage the highest levels of pSmad1 co-localize with CV2 protein in the vb and are complementary to the expression domain of *Bmp*, *Tsg*, *Chd*, *Chd1-1*, *Chd1-2* and *Tolloid* mRNAs in the ivd.

the absence of the tracheal cartilage rings that physically support the shape of the trachea (see insets in Figs. 1D and D') and express CV2 protein (Fig. 1B').

#### *Expression patterns of Cv2, Tsg, Chd and Chdl-1 in the vertebral column*

To better understand the *Cv2*<sup>-/-</sup> phenotype, the expression domain of *Cv2* was compared to those of other regulators of the BMP pathway, such as *Tsg*, *Chd*, *Chdl-1* and *Chdl-2*, which also bind to BMP4 (Oelgeschläger et al., 2000; Nakayama et al., 2004; Zhang et al., 2007). *In situ* hybridization on sections of 12.5 d.p.c. wild-type embryos using *Cv2*, *Tsg*, *Chd*, *Chdl-1* (Figs. 2A–D') and *Chdl-2* (not shown) probes, revealed that *Cv2* is expressed in the future vertebral bodies while *Tsg*, *Chd*, *Chdl-1* and *Chdl-2* are all expressed in the intervertebral disc region together with *Bmp4* (Zakin and De Robertis, 2004) and the Tolloid metalloproteinase *Bmp1/Tll1* (Fig. 4J and data not shown). These expression patterns are also similar at early prevertebral stages (data not shown). In the *Drosophila* wing, the expression patterns for *Cv2*, *Chd/Sog*, *Bmp/Dpp* and *Bmp1/Tlr* are complementary: *Dpp* (*Decapentaplegic*) is present in the longitudinal veins, *Sog*, *Tlr*, *dTsg2* and *Gbb* (*glass bottom boat*, a BMP ligand) in the intervein regions, and CV2 protein is specifically localized to the crossveins, in which BMP signaling is maximal (Blair, 2007; Serpe et al., 2008). This suggested to us that other proteins made at a distance, such as *Tsg*, or the related proteins *Chd*, *Chdl-1* and *Chdl-2*, might diffuse and interact with CV2 protein that remains anchored in the vertebral body cartilage in which it is transcribed (Figs. 1B and 2A, A').

#### *CV2 regulates the phosphorylation state of Smad1 during vertebral development*

To determine whether *Cv2* mutant phenotypes resulted from a pro- or anti-BMP activity of CV2, the levels of phosphorylated Smad1 (pSmad1), a direct downstream effector of BMP signaling, were analyzed in the differentiating vertebrae. Because the vertebral column forms sequentially (starting from the anterior), we compared in detail the histological structures, levels of Smad1 phosphorylation, and localization of CV2 protein at anterior and posterior locations (Figs. 3 and 4). In the posterior region of 12.5 d.p.c. embryos, the early vertebral column anlage is subdivided into uncondensed and condensed mesenchymes, which correspond to the future vertebral body and intervertebral disc, respectively (Figs. 3A–F). No anatomical differences could be found at this stage in *Cv2*<sup>-/-</sup> compared to wild-type, but the peak of pSmad1 signal detected in the condensed mesenchyme was lost in the mutant (compare Figs. 3G to H). Surprisingly, the domain defective for Smad1 phosphorylation did not co-localize with the domain of highest CV2 protein expression (compare Figs. 3G to I). These results indicated that CV2 is required to facilitate BMP signaling in a domain adjacent to, but not overlapping, the site of CV2 expression. One possible explanation could be that in *Cv2* mutants inhibitory Tsg/Chd/BMP4 or Tsg/Chdl/BMP4 complexes accumulate in the intervertebral region and are unable to signal. This would be in agreement with the finding that CV2 is a potent Chordin binding protein (Ambrosio et al., 2008) that would attract diffusing Chd/Tsg/BMP complexes to its site of expression in the future vertebral cartilage. These observations in the early developing vertebral field are summarized in Fig. 3J.

In the more developed anterior region of the 12.5 d.p.c. vertebral column, the vertebral bodies (in which CV2 is expressed) were reduced in *Cv2*<sup>-/-</sup> mutants (Fig. 4, panels C–F). The reduced vertebral body size might be explained by the failure to concentrate Tsg/Chd/BMP complexes in the vertebral cartilage (Ambrosio et al., 2008). The affected vertebral bodies coincided with maximal pSmad1 levels in both wild-type and *Cv2*<sup>-/-</sup> embryos. The area of pSmad1 signal was reduced in *Cv2*<sup>-/-</sup> (as was the cartilage), but was still clearly detected. At this more mature anterior level of the vertebral column, the

expression of CV2 and pSmad1 proteins co-localized (compare Figs. 4G and I). A summary of these results is presented in Fig. 4J. Biochemically, no significant differences were observed in total pSmad1 levels of whole tail extracts of wild-type and mutant 12.5 d.p.c. embryos (Fig. 5A). This might be explained by the presence in the tail of a heterogeneous population of multiple tissues at various stages of differentiation, thus diluting any differences in the levels of pSmad1.

#### *BMP-inhibitory effects of CV2 in mutant MEFs*

Because MEFs are of mesodermal origin, the same germ layer that is affected in *Cv2*<sup>-/-</sup> embryos, the effect of CV2 protein on BMP signaling was analyzed in the CV2 mutant background (Fig. 5B). Upon addition of 0.3 or 1 nM of BMP4 to *Cv2*<sup>-/-</sup> MEFs, Smad1 phosphorylation was induced in a dose-dependent manner (Fig. 5B, compare lanes 1, 3 and 5). This activation of pSmad1 was repressed by the addition of 1 nM CV2 protein (compare lanes 3 to 4 and 5 to 6). Note that CV2 inhibited BMP4 signaling even at equimolar amounts (Fig. 5B, lanes 5, 6). Similar inhibition of pSmad1 by CV2 protein was observed when wild-type MEFs were used (not shown). Importantly, the phosphorylation of Smad1 was higher in *Cv2*<sup>-/-</sup> MEFs compared to wild-type after addition of BMP4 (Fig. 5C, compare lanes 5 and 6). These experiments indicate that CV2 functions as an endogenous BMP signaling antagonist in fibroblasts in culture.

The pSmad1 staining in the developing vertebral column confirms that CV2 can have a pro-BMP activity *in vivo* in the future intervertebral disc (compare Figs. 3G and H, brackets). However, this occurs only at a distance from the CV2 protein expression site, suggesting that the defective BMP signaling phenotype results indirectly from a change in the activity of BMP signaling gradients. The CV2 protein remains anchored at its site of synthesis in the prevertebral body (Figs. 1B, 3I). In the absence of CV2 in vertebral bodies, inhibitory Tsg/Chd/BMP complexes may remain in the intervertebral region, resulting in the reduction in BMP signaling. In fibroblasts lacking *Cv2*, the response to BMP signaling was increased, suggesting that CV2 functions cell-autonomously as a BMP antagonist. These results may be explained through an interplay between CV2 and other BMP regulators (such as *Tsg*, *Chd*, *Chdl-1* and *Chdl-2*) in the context of the flow of BMP-containing protein complexes in the developing vertebral morphogenetic field directed by CV2 protein (see Discussion below).

We next analyzed pSmad1 levels in double mutant MEFs for CV2 and *Chd*. The response of *Cv2*<sup>-/-</sup>, *Chd*<sup>-/-</sup>, or *Cv2*<sup>-/-</sup>; *Chd*<sup>-/-</sup> MEFs to low levels of BMP4 (0.3 nM) was increased in all cases compared to fibroblasts from their wild-type siblings (Fig. 5C, lanes 5 to 8). Upon addition of increasing amounts of BMP4 protein, it was observed that *Cv2*<sup>-/-</sup>; *Chd*<sup>-/-</sup> double mutant MEFs showed a stronger BMP4 signaling response than wild-type MEFs at low BMP4 levels (0.1 and 0.3 nM) (Fig. 5D, lanes 3–6) but responded similarly at high BMP4 levels (1 nM) (Fig. 5D, lanes 7, 8). Please note that in all our MEF studies the effects of BMP4 addition on pSmad1 were analyzed after only 30 min of addition. Thus, our experiments reflect the initial BMP receptor activation and represent a direct readout of BMP4 signaling activity. These results in mutant MEFs show that the overall function of endogenous CV2 and *Chd* in fibroblasts is to serve as BMP4 antagonists. This is in agreement with loss-of-function studies in the *Xenopus* gastrula (Ambrosio et al., 2008).


#### *A weak genetic interaction between Cv2 and Chd*

We next investigated whether *Cv2* and *Chd* mouse mutants displayed genetic interactions. Mouse strains carrying the *Cv2* and *Chd* (Bachiller et al., 2003) mutations were crossed to generate *Cv2*<sup>+/-</sup>; *Chd*<sup>+/-</sup> mating pairs whose progeny was subsequently analyzed in late embryos before birth. Out of 159 embryos, all genotypes were

recovered in the expected proportions except for the  $Cv2^{+/-}; Chd^{-/-}$  and  $Cv2^{+/-}; Chd^{-/-}$  embryos which were recovered in lower numbers than predicted by the mendelian ratio (Supplementary Table 1). This observation was in agreement with previous findings of early lethality in a small percentage of  $Chd$  mutants (Bachiller et al., 2003).

Bone formation is affected in both  $Cv2^{-/-}$  and  $Chd^{-/-}$  mutants and compound mutant skeletons were analyzed for possible interactions (Figs. 5E–H). Surprisingly, no significant effects were found in  $Cv2^{-/-}; Chd^{-/-}$  double mutants; in particular the characteristic posterior homeotic transformation of the 13th thoracic vertebra present in  $Cv2^{-/-}$  was unaffected by the loss of Chordin (Figs. 5E–H). Conversely,

the  $Chd$  mutant phenotype was unchanged by  $Cv2$  dosage. A weak recovery of the neural arches in the lumbar region of  $Cv2^{-/-}; Chd^{-/-}$  compared to  $Cv2^{-/-}; Chd^{+/-}$  was observed in some embryos (Figs. 5G, H and Supplementary Table 2), which would indicate opposing effects of  $CV2$  and  $Chd$ . However, given that this weak rescue was limited to the lumbar neural arches, while the numerous other skeletal defects in both mutants showed no change, the functional significance of this interaction is difficult to evaluate. We propose that the lack of a strong interaction between  $Cv2$  and  $Chd$  in vertebral column development may be explained by the redundant anti-BMP activity of  $Chd1-1$  and  $Chd1-2$  molecules which have similar functions to  $Chd$



**Fig. 5.** Western blot analyses of Smad1 phosphorylation in whole tails, MEFs derived from wild-type,  $Cv2^{-/-}$ ,  $Chd^{-/-}$  and  $Cv2^{-/-}; Chd^{-/-}$  treated with BMP4 protein, and lack of skeletal genetic interactions between  $Cv2$  and  $Chd$  mutants. (A) Western blot showing comparable amounts of endogenous Smad1 phosphorylation in tails from wild-type,  $Cv2^{-/-}$  and  $Cv2^{+/-}$  12.5 mouse d.p.c. embryos. The tail contains multiple tissues in addition to the vertebral column which is the topic of this study. No significant differences in pSmad1 are seen. (B) Addition of purified CV2 protein to  $Cv2^{-/-}$  MEFs inhibits Smad1 phosphorylation induced by 30 min treatment with BMP4. (C) pSmad1 levels are higher in  $Cv2^{-/-}$ ,  $Chd^{-/-}$  and  $Cv2^{-/-}; Chd^{-/-}$  MEFs compared to wild-type fibroblasts upon addition of 0.3 nM of BMP4 (compare lane 5 to lanes 6–8). (D) pSmad1 response levels are higher in  $Cv2^{-/-}; Chd^{-/-}$  MEFs compared to wild-type at low amounts of BMP4 (compare lanes 3 to 4, and 5 to 6). (E–H) Genetic interaction between  $Cv2$  and  $Chd$  in the lumbar region of the vertebral column. Bone is stained with Alizarin Red and cartilage with Alcian Blue. Dorsal view of the skeletons of wild-type (E),  $Chd^{-/-}$  (F),  $Cv2^{-/-}$  (G) and  $Cv2^{-/-}; Chd^{-/-}$  (H) neonates. In this region the skeleton of  $Chd^{-/-}$  (F) is indistinguishable from wild-type (E). The posterior homeotic transformation indicated by the loss of the 13th rib (asterisk) is present in  $Cv2^{-/-}$  and  $Cv2^{-/-}; Chd^{-/-}$  embryos. na, neural arches.

**Table 1**  
Suppression of the  $Cv2^{-/-}$  lethal phenotype by  $Tsg$  loss-of-function. Genotypes of neonates obtained from  $Cv2^{+/+}; Tsg^{+/+}$  intercrosses

Genotype	Number of embryos	Observed percentage (expected percentage)	Number of embryos with $Cv2$ skeletal phenotype <sup>a</sup> (%)
$Cv2^{+/+}; Tsg^{+/+}$	8	9 (6.25)	
$Cv2^{+/+}; Tsg^{+/-}$	12	14 (12.5)	
$Cv2^{+/+}; Tsg^{-/-}$	9	10.5 (12.5)	
$Cv2^{-/-}; Tsg^{+/+}$	23	27 (25)	
$Cv2^{-/-}; Tsg^{-/-}$	4	5 (6.25)	
$Cv2^{-/-}; Tsg^{+/-}$	8	9 (12.5)	
$Cv2^{-/-}; Tsg^b$	5	6 (6.25)	5 (100%)
$Cv2^{-/-}; Tsg^c$	9	10.5 (12.5)	8 (90%)
$Cv2^{-/-}; Tsg^d$	8	9 (6.25)	0 (0%)
Total	86		

<sup>a</sup>  $Cv2$  skeletal phenotypes include lack of the 13th rib and deltoid tuberosity, skull phenotype, and absence of the tracheal rings. Because defective neural arches and shorter tails are also found in  $Tsg$  mutants, this phenotype was not taken into account in this table.

<sup>b</sup> All died as neonates.

<sup>c</sup> Most died as neonates.

<sup>d</sup> Some of these animals were recovered alive at day 3 post-partum; since these  $Cv2^{-/-}; Tsg^{-/-}$  mutants displayed the  $Tsg^{-/-}$  skeletal phenotype we conclude that  $Tsg$  is genetically epistatic over  $Cv2$ . The rescue of the  $Cv2^{-/-}$  phenotype in  $Cv2^{-/-}; Tsg^{-/-}$  was found to be statistically significant using a chi-square test for independence ( $p < 0.001$ ).

(Nakayama et al., 2001, 2004) and are co-expressed with  $Chd$  in the mouse (Figs. 2 and 4j). In conclusion, it is likely that uncovering a genetic interaction between  $Cv2$  and  $Chd$  will require simultaneous inactivation of  $Chdl-1$  and  $Chdl-2$ .

#### Mutation of $Tsg$ suppresses $Cv2$ loss-of-function phenotypes, including lethality

We next analyzed the interaction between  $Cv2$  and  $Tsg$  in compound heterozygous knockout mice for  $Cv2$  (this work) and  $Tsg$  (Zakin and De Robertis, 2004). The genotype frequencies of the progeny of  $Cv2^{+/+}; Tsg^{+/+}$  intercrosses are presented in Table 1. Of 86 neonates, the  $Cv2^{+/+}; Tsg^{-/-}$  and  $Cv2^{-/-}; Tsg^{-/-}$  genotypes were obtained at slightly lower values than expected, perhaps due to an early lethality of  $Tsg^{-/-}$  or to statistical error.  $Cv2^{-/-}; Tsg^{-/-}$  neonates were recovered in a higher percentage than expected (9%, 6.25% expected,  $n=8$ ). More importantly,  $Cv2^{-/-}; Tsg^{-/-}$  pups survived, while all  $Cv2^{-/-}$  neonates died at birth. When  $Cv2^{-/-}; Tsg^{-/-}$  skeletons were analyzed, they resembled  $Tsg^{-/-}$  with most  $Cv2^{-/-}$  skeletal phenotypes being rescued (Fig. 6). In all  $Cv2^{-/-}; Tsg^{-/-}$  neonates normal tracheal rings were present, probably explaining why the animals survive (compare Figs. 6B and D). The deltoid tuberosity of the humerus (compare Figs. 6F and H), the defects in the base of the skull (not shown), the neural arches (compare Figs. 6N and P), and the 13<sup>th</sup> rib lost in  $Cv2^{-/-}$  (compare Figs. 6J and L) were all rescued in  $Cv2^{-/-}; Tsg^{-/-}$  animals. We conclude from these results that  $CV2$  function requires  $Tsg$ , and that  $Tsg$  is epistatic to  $Cv2$ .

#### BMP signaling in $Cv2^{-/-}; Tsg^{-/-}$ MEFs

We next tested whether  $Tsg$  was also epistatic in double mutants MEFs (Fig. 7A). In these experiments we used quantitative infrared Western blots using anti-rabbit pSmad1 in green for signaling and anti-mouse  $\alpha$ -Tubulin in red as loading control. The signal intensities were measured in a Li-Cor infrared scanner, and histograms quantified pSmad1 signaling 30 min after addition of BMP4 are shown below each lane. Phosphorylated Smad1 levels were slightly higher in  $Cv2^{-/-}$  fibroblasts compared to wild-type after the addition of 0.3 nM BMP4 (Fig. 7A, compare lanes 3 and 4). However, they were substantially reduced in  $Cv2^{-/-}; Tsg^{-/-}$  MEFs (Fig. 7A, compare lane 2 to 3 and 4), or in  $Tsg^{-/-}$  single mutants (Fig. 7A, compare lane 2 to 1). Note that BMP signaling was impaired in  $Tsg^{-/-}$  fibroblasts, demonstrating the pro-

BMP effect of endogenous  $Tsg$ , and that this phenotype was dominant in  $Cv2^{-/-}; Tsg^{-/-}$  mutants (Fig. 7A, see histograms for lanes 1 and 2).

To further study the interaction between  $Cv2$  and  $Tsg$ , the activities of these proteins was analyzed after addition to  $Cv2^{-/-}; Tsg^{-/-}$  MEFs (Fig. 7B). As previously noted, addition of CV2 protein to fibroblasts inhibited BMP signaling (Fig. 7B, compare lanes 2 and 3), while the simultaneous addition of 1 nM CV2 and  $Tsg$  lowered pSmad1 levels even more efficiently (Fig. 7B, lanes 3 and 5 and histogram below). We also tested the effect of the triple addition of CV2,  $Tsg$  and  $Chd$  proteins to  $Cv2^{-/-}; Tsg^{-/-}$  MEFs (Supplementary Fig. 3). This experiment indicated that when  $Chd$ , CV2 and BMP4 were added together, the inhibition of Smad1 phosphorylation was stronger than that obtained for CV2 or  $Chd$  alone (Supplementary Fig. 3, compare lane 7 to 4 and 6), indicating potent anti-BMP effects of CV2 in combination with  $Chd$ . Finally, when all the components ( $Tsg$ , CV2,  $Chd$  and BMP4) were present, the overall effect was an even stronger reduction of pSmad1 levels (Supplementary Fig. 3, compare lanes 2 and 9). In conclusion, the effect of simultaneous addition of  $Chd$ , CV2 and  $Tsg$  to fibroblasts lacking CV2 and  $Tsg$  is to inhibit BMP signaling.

In a different experimental design (Fig. 7C), CV2 protein was preincubated with the double mutant fibroblasts for 10 min, washed, and the supernatant replaced by medium containing BMP4 alone or BMP4 together with  $Tsg$  protein. In this experimental situation, the only CV2 present would be tethered to the cell surface (Fig. 7C). This setting should mimic better the *in vivo* situation in which CV2 serves as a co-receptor anchored at the cell surface (Serpe et al., 2008). While the reduction of BMP4 signaling levels by CV2 alone was less efficient in this experimental setting (Fig. 7C, compare lanes 2 and 3), the addition of  $Tsg$  and CV2 had a synergistic inhibitory effect on BMP4 signaling (Fig. 7C, compare lanes 3 and 5). This indicates that  $Tsg$  protein promotes the CV2 anti-BMP activity in fibroblasts, as it does in *Xenopus* embryos (Ambrosio et al., 2008).


Taken together, these results lead us to propose that the CV2 secreted protein helps establish morphogenetic fields of BMP signaling between intervertebral and vertebral regions of the vertebral column. In mouse fibroblasts, CV2 displays overall an anti-BMP activity. *In vivo*, CV2 would be required, in combination with  $Tsg$ , for the proper localization of the BMP morphogenetic signal to the vertebral cartilage.

## Discussion

This study was undertaken to understand the role of CV2,  $Tsg$  and  $Chd$  interactions and their effect on BMP signaling during mouse embryogenesis. It was found that  $Cv2$  is essential for survival at birth and for proper skeletogenesis, in agreement with independent work of Ikeya et al. (2006). We propose that this skeletal phenotype is due to a defective localization of the BMP signal in the developing vertebral bodies, in which the CV2 protein is located. The most interesting observation reported here is that the lack of  $Tsg$  rescued most  $Cv2^{-/-}$  phenotypes, including lethality (Fig. 6). We propose that the phenotype caused by the loss of  $Cv2$  is the result of changes in  $Tsg$  activity, which functions in conjunction with other  $Tsg$ -binding proteins, such as  $Chd$ ,  $Chdl-1$  and  $Chdl-2$  (Oelgeschlager et al., 2000; Nakayama et al., 2004; Zhang et al., 2007), to regulate the flow of BMP morphogenetic signals between the developing intervertebral and vertebral regions.

#### The biochemical functions of CV2 in embryos

Our understanding of the function of CV2 has been advanced by recent work (reviewed by Bier, 2008). In *Xenopus*, CV2 is expressed in the high-BMP region (ventral center) of the gastrula, where it functions as a local feedback inhibitor of BMP signaling (Ambrosio et al., 2008). Double knockdowns of CV2 and  $Chd$  present very high BMP signaling levels, and these suggested both proteins might



**Fig. 6.** *Tsg* is epistatic over *Cv2*: the loss of *Tsg* in *Cv2*<sup>-/-</sup> suppresses most of the *Cv2* mutant skeletal phenotypes. Skeletal preparations of wild-type (A, E, I, M), *Cv2*<sup>-/-</sup> (B, F, J, N), *Tsg*<sup>-/-</sup> (C, G, K, O) and *Cv2*<sup>-/-</sup>; *Tsg*<sup>-/-</sup> (D, H, L, P) neonates stained with Alizarin Red and Alcian Blue. (A–D) The cervical neural arches (na) are reduced in *Cv2*<sup>-/-</sup> but are rescued in *Cv2*<sup>-/-</sup>; *Tsg*<sup>-/-</sup> double mutants. The tracheal rings (tr) are missing in *Cv2*<sup>-/-</sup> (red asterisk in B), but the tracheal (t) cartilage develops like wild-type (A) in *Cv2*<sup>-/-</sup>; *Tsg*<sup>-/-</sup> double mutants (D). (E–H). *Cv2*<sup>-/-</sup> lack the humerus/deltoid tuberosity (dt), which is rescued in *Cv2*<sup>-/-</sup>; *Tsg*<sup>-/-</sup>. (I–L) The posterior homeotic transformation of T13 (black asterisks) in *Cv2*<sup>-/-</sup> (J) is rescued in *Cv2*<sup>-/-</sup>; *Tsg*<sup>-/-</sup> (L); however the ossification centers (oc) remain defective. (M–P) Side views of the lumbar region. Neural arches (na) are reduced in *Cv2*<sup>-/-</sup> (N) but are only mildly affected in *Cv2*<sup>-/-</sup>; *Tsg*<sup>-/-</sup> (P), as is the case in *Tsg*<sup>-/-</sup> mutants (O).


interact. In biochemical studies CV2 was found to bind to Chordin with high affinity, and to Chordin/BMP or Chordin digestion products by tolloids with even higher affinity (Ambrosio et al., 2008). This led to the proposal that the pro-BMP effects of CV2 may be caused by directing the flow of Tsg/Chd/BMP complexes towards the ventral sites of CV2 expression (Ambrosio et al., 2008). The flow of BMP4 towards more ventral regions is known to require Chd in the *Xenopus* gastrula (Ben-Zvi et al., 2008). CV2 has an anti-Chd activity in *Xenopus*, since CV2 depletion causes the embryo to become hypersensitive to microinjected Chordin protein (Ambrosio et al., 2008). This suggests that cell surface CV2 may be involved in the clearing of Chd, or Chd degradation products, from the extracellular space. The net signaling effect of CV2 is dependent on the activity of the metalloproteinase Xolloid-related (Xlr) which cleaves Chd (but not CV2). In the absence of Xlr, CV2 removes BMP/Chd complexes, presumably by endocytosis, causing its anti-BMP effect. In the presence of Xlr, complexes of Tsg/Chd/BMP4, perhaps already bound to CV2, are clipped by Xlr, releasing BMP for peak signaling in the ventral side (Ambrosio et al., 2008).

In the *Drosophila* wing, CV2 is expressed in the crossveins, a region of peak BMP activity (Conley et al., 2000; Blair, 2006). The CV2 secreted protein remains tethered to its site of synthesis and does not diffuse more than two cell diameters, by virtue of its tight binding to a GPI-tethered heparin sulfate proteoglycan (HSPG) named Dally (Serpe

et al., 2008). In zebrafish, CV2 also shows tight binding to HSPGs (Rentzsch et al., 2006). Importantly, CV2 also interacts with the BMP Type I receptor Thickveins (Tkv) (Serpe et al., 2008). This raises the intriguing possibility that CV2 may facilitate BMP signaling by bringing Dpp/Tsg2/Sog complexes in close proximity of BMP receptors (Serpe et al., 2008). In mammals, we have confirmed this interaction in vitro using commercial BMPR-1a (ALK-3) and CV2 proteins (A.L. Ambrosio and E.M.D.R., unpublished). It has been proposed that low levels of CV2 help deliver Dpp to Tkv, whereas high CV2 levels inhibit Dpp signaling in the crossvein (Serpe et al., 2008; Bier, 2008). Thus, both in vertebrates and in *Drosophila* profound strides have been made in unraveling how CV2, Tsg and Chd regulate the formation of BMP gradients.

#### *Cv2* behaves as a local BMP antagonist in MEFs

The loss of CV2 resulted in multiple abnormalities in cartilages and bones of the skeleton (e.g. vertebrae, 13th rib, trachea, deltoid tuberosity of the humerus and basisphenoid). These defects may originate from the defective maturation of cartilage-producing cells (Ikeya et al., 2006). On the one hand, these phenotypes can be interpreted as decreased BMP signaling; in particular the loss of the 13<sup>th</sup> rib has been described in mutants for *Bmp4* (Lawson et al., 1999),



**Fig. 7.** Western blot analyses of Smad1 phosphorylation in *Cv2<sup>-/-</sup>; Tsg<sup>-/-</sup>* double mutant MEFs. Signals generated by infrared conjugated secondary antibodies were detected using the Li-Cor Odyssey imager. In the bottom blot, the artificial colors red and green correspond to signals detected at  $\lambda$ 680 nm (anti-mouse secondary antibody against the  $\alpha$ Tubulin antibody used here as loading control) and 800 nm (anti-rabbit secondary antibody against the pSmad1 antibody), respectively. The infrared imager system allows quantification of the relative pSmad1 levels with respect to total protein loading and this is shown in the histograms at the bottom of the blots. (A) pSmad1 levels are reduced in *Tsg<sup>-/-</sup>* and *Cv2<sup>-/-</sup>*; *Tsg<sup>-/-</sup>* MEFs when compared with *Cv2<sup>-/-</sup>* or wild-type fibroblasts upon addition of 0.3 nM of BMP4, indicating that BMP4 signaling is impaired in the absence of Tsg (pro-BMP effect of Tsg) and that this is not affected by removal of CV2. (B) Effects of exogenous CV2 and Tsg on BMP4 signaling in *Cv2<sup>-/-</sup>; Tsg<sup>-/-</sup>* MEFs. Simultaneous addition of CV2 and Tsg proteins inhibited BMP signaling more efficiently than CV2 alone, demonstrating that Tsg promotes the anti-BMP effects of CV2. (C) Experiments in which CV2 was preincubated with *Cv2<sup>-/-</sup>; Tsg<sup>-/-</sup>* MEFs for 10 min and subsequently washed to remove excess CV2, leaving only CV2 bound to the cell surface. Note that the inhibition of BMP signaling was stronger in the presence of Tsg preincubated with BMP4 (anti-BMP effect of Tsg).

*Bmp5* (Green and Green, 1946), *Bmp7* (Luo et al., 1995) and *Bmpr2* (Delot et al., 2003). Similarly, the loss of the deltoid tuberosity was observed in *Bmp7<sup>-/-</sup>*; *Bmpr1b<sup>-/-</sup>* (Suzuki et al., 1996). The defects in vertebral neural arches could be attributed to either pro- or anti-BMP activities since they are observed in mutants for the BMP antagonist *Chd* (Bachiller et al., 2003), for the pro-BMP *Tsg* (Zakin and De Robertis, 2004) or for *Bmp7* (Jena et al., 1997).

We have derived *Cv2<sup>-/-</sup>*, *Cv2<sup>-/-</sup>*; *Chd<sup>-/-</sup>*, and *Cv2<sup>-/-</sup>*; *Tsg<sup>-/-</sup>* MEFs that will be very useful to the field. We used these new reagents to examine the effect of the mutations on Smad1 phosphorylation 30 min after BMP addition. In fibroblasts in culture, the flow of BMP signals, as in intact embryos, should not play a functional role. When analyzed in culture, all single and double mutants indicated that CV2 behaved as an endogenous BMP antagonist in embryonic fibroblasts (Figs. 5 and 7). This is in agreement with the effect of morpholino depletions in *Xenopus*, in which *Chd* and CV2 are overall BMP antagonists (Ambrosio et al., 2008). In the case of *Tsg<sup>-/-</sup>* fibroblasts, or *Cv2<sup>-/-</sup>*; *Tsg<sup>-/-</sup>* BMP signaling was reduced (Fig. 7A, lanes 1 and 2), supporting a pro-BMP function of *Tsg* (Oelgeschläger et al., 2000; Little and Mullins, 2006; Ambrosio et al., 2008). These results contrast with the report that *Cv2<sup>-/-</sup>* MEFs had reduced expression of cartilage markers 48 h after BMP treatment (Ikeya et al., 2006). Since our measurements were performed 30 min after treatment we believe they represent a more direct readout of BMP signaling. Perhaps the results of the Sasai group are caused by binding of BMP, and *Chd*, to CV2 on the cell surface with subsequent release by tolloids after 48 h in tissue culture.

In conclusion, our *Cv2<sup>-/-</sup>* MEFs results as well as studies on the *Drosophila* wing (Ralston and Blair, 2005; Blair, 2007; Serpe et al., 2008) and the *Xenopus* gastrula (Ambrosio et al., 2008), suggest that the pro-BMP *Cv2* phenotypes may be caused by changes in BMP distribution in morphogenetic fields. The *Chd*-binding activity of CV2 would help generate a BMP gradient so that peak BMP signaling results from the diffusion of *Tsg/Chd/BMP* complexes from the intervertebral region towards the vertebral body where *Cv2* expression is high, serving to concentrate *Tsg/Chd/BMP*. Upon digestion of *Chd* by tolloid metalloproteinases, the released BMPs would be able to signal (Piccolo et al., 1997) while at low levels of tolloids CV2 would serve as a BMP antagonist by clearing *Chd* complexes (Ambrosio et al., 2008). In the *Drosophila* embryo, the flow of Dpp-GFP towards the dorsal midline of the *Drosophila* embryo has been documented (Wang and Ferguson, 2005), and shown to require endogenous *Tsg/Sog/Dpp* (Eldar 2002). Related observations have been made in *Xenopus* (Ben-Zvi et al., 2008).

We now propose a model in which the flow of BMP4-containing complexes towards CV2 expressing regions establishes a vertebral morphogenetic field. Although not yet tested directly, CV2 in the vertebral body might also concentrate the Chordin-like proteins, *Chd1-1* and *Chd1-2*, produced in the intervertebral disc, which are also able to bind BMP4 and *Tsg*. We did not observe significant genetic interactions between *Cv2* and *Chd*, which may be explained by *Chd1-1* and *Chd1-2* activities which are redundant with *Chd* (Nakayama et al., 2004; Zhang et al., 2007).

#### *The function of Cv2 in the vertebral column requires Tsg*

In *Drosophila*, mutations in *dTsg2* (*Cv1*) or *Cv2* produce similar crossveinless phenotypes, indicating possible interaction between these molecules (Conley et al., 2000; Shimmi et al., 2005; Vilmos et al., 2005). In *Xenopus*, *Tsg* is strongly required for BMP signaling in *Cv2*-depleted embryos (Ambrosio et al., 2008). In the mouse, we now report a strong genetic interaction between *Cv2* and *Tsg* during development: all *Cv2<sup>-/-</sup>* skeletal phenotypes, and lethality, were rescued in *Cv2<sup>-/-</sup>*; *Tsg<sup>-/-</sup>* animals, showing that *Tsg* is epistatic over *Cv2*. In the absence of *Tsg*, BMP provides only a local signal that manifests itself in the *Tsg<sup>-/-</sup>* phenotype (Nosaka et al., 2003; Petryk

et al., 2004; Zakin and De Robertis, 2004). In *Cv2<sup>-/-</sup>*; *Tsg<sup>-/-</sup>* double mutants the *Tsg* phenotype is epistatic because the other CR domain BMP-binding proteins—such as *Chd*, *Chd1-1* and *Chd1-2*—also require *Tsg* activity in order to contribute to the morphogenetic gradient.

In conclusion, the recent work in the *Drosophila* wing (Serpe et al., 2008) and the *Xenopus* gastrula (Ambrosio et al., 2008) support the view that CV2 functions to shape the *Tsg/Chd/BMP* gradient. *Tsg* would be required for the expression of the *Cv2* phenotype because it is required for the flow of BMP4 complexes toward sites of CV2 expression. We propose, by analogy to the cases of the crossvein of the *Drosophila* wing and the *Xenopus* gastrula, that in the mammalian vertebral column the CV2/*Chd/Tsg/BMP/Tolloid* pathway may ultimately shape a morphogenetic field of BMP signaling that determines the choice between vertebral cartilage or intervertebral cell differentiation fates. This extracellular signaling network may contribute to the great evolutionary variability of vertebral morphology in the mammals. For example, the vast majority of mammals—including mice, humans and giraffes—have seven cervical vertebrae despite obvious differences in body size and shape.

#### Acknowledgments

The authors would like to thank D. Geissert and T. Boe for technical assistance and members of our laboratory for comments on the manuscript. The late Mario Zakin provided invaluable biochemical insights. R.I.P. Thanks to Dr. P. Perlman of the Howard Hughes Medical Institute for leadership in the public availability of our *Cv2*, *Tsg* and *Chd* mouse strains via the Jackson Laboratories. This work was supported by the Norman Sprague endowment (UCLA). E.M.D.R. is an investigator and L.Z. a research specialist of the Howard Hughes Medical Institute.

#### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ydbio.2008.08.019.

#### References

- Ambrosio, A.L., Taelman, V.F., Lee, H.X., Metzinger, C.A., Coffinier, C., De Robertis, E.M., 2008. Crossveinless-2 is a BMP feedback inhibitor that binds *Chd/BMP* to regulate *Xenopus* embryonic patterning. *Dev. Cell* 15, 248–260.
- Bachiller, D., Klingensmith, J., Kemp, C., Belo, J.A., Anderson, R.M., May, S.R., McMahon, J.A., McMahon, A.P., Harland, R.M., Rossant, J., De Robertis, E.M., 2000. The organizer factors Chordin and Noggin are required for mouse forebrain development. *Nature* 403, 658–661.
- Bachiller, D., Klingensmith, J., Shneyder, N., Tran, U., Anderson, R., Rossant, J., De Robertis, E.M., 2003. The role of Chordin/BMP signals in mammalian pharyngeal development and DiGeorge syndrome. *Development* 130, 3567–3578.
- Ben-Zvi, D., Ben-Zion, S., Fainsod, A., Barkai, N., 2008. Scaling of the BMP activation gradient in *Xenopus* embryos. *Nature* 453, 1205–1211.
- Bier, E., 2008. Intriguing extracellular regulation of BMP signaling. *Dev. Cell* 15, 176–177.
- Binnerts, M.E., Wen, X., Cante-Barrett, K., Bright, J., Chen, H.T., Asundi, V., Sattari, P., Tang, T., Boyle, B., Funk, W., Rupp, F., 2004. Human Crossveinless-2 is a novel inhibitor of bone morphogenetic proteins. *Biochem. Biophys. Res. Commun.* 315, 272–280.
- Blair, S.S., 2007. Wing vein patterning in *Drosophila* and the analysis of intercellular signaling. *Annu. Rev. Cell Dev. Biol.* 23, 293–319.
- Coffinier, C., Tran, U., Larrain, J., De Robertis, E.M., 2001. Neuralin-1 is a novel Chordin-related molecule expressed in the mouse neural plate. *Mech. Dev.* 100, 119–122.
- Coffinier, C., Ketpura, N., Tran, U., Geissert, D., De Robertis, E.M., 2002. Mouse Crossveinless-2 is the vertebrate homolog of a *Drosophila* extracellular regulator of BMP signaling. *Gene Expr. Patterns* 2, 189–194.
- Coles, E., Christiansen, J., Economou, A., Bronner-Fraser, M., Wilkinson, D.G., 2004. A vertebrate crossveinless 2 homologue modulates BMP activity and neural crest cell migration. *Development* 131, 5309–5317.
- Conley, C.A., Silburn, R., Singer, M.A., Ralston, A., Rohwer-Nutter, D., Olson, D.J., Gelbart, W., Blair, S.S., 2000. Crossveinless 2 contains cysteine-rich domains and is required for high levels of BMP-like activity during the formation of the crossveins in *Drosophila*. *Development* 127, 3947–3959.
- De Robertis, E.M., Kuroda, H., 2004. Dorsal–Ventral Patterning and Neural Induction in *Xenopus* Embryos. *Annu. Rev. Cell Dev. Biol.* 20, 285–308.
- Delot, E.C., Bahamonde, M.E., Zhao, M., Lyons, K.M., 2003. BMP signaling is required for septation of the outflow tract of the mammalian heart. *Development* 130, 209–220.

- Eldar, A., Dorfman, R., Weiss, D., Ashe, H., Shilo, B.Z., Barkai, N., 2002. Robustness of the BMP morphogen gradient in *Drosophila* embryonic patterning. *Nature* 419, 304–308.
- Green, E.L., Green, M.C., 1946. Effect of the short ear gene on number of ribs and presacral vertebrae in the house mouse. *Am. Nat.* 80.
- Hogan, B.L., 1996. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. *Genes Dev.* 10, 1580–1594.
- Hogan, B.L., Beddington, R., Costantini, F., Lacy, E., 1994. *Manipulating the Mouse Embryo*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Ikeya, M., Kawada, M., Kiyonari, H., Sasai, N., Nakao, K., Furuta, Y., Sasai, Y., 2006. Essential pro-Bmp roles of crossveinless 2 in mouse organogenesis. *Development* 133, 4463–4473.
- Jena, N., Martin-Seisdedos, C., McCue, P., Croce, C.M., 1997. BMP7 null mutation in mice: developmental defects in skeleton, kidney, and eye. *Exp. Cell Res.* 230, 28–37.
- Kamimura, M., Matsumoto, K., Koshiba-Takeuchi, K., Ogura, T., 2004. Vertebrate crossveinless 2 is secreted and acts as an extracellular modulator of the BMP signaling cascade. *Dev. Dyn.* 230, 434–445.
- Larrain, J., Oelgeschlager, M., Ketpura, N.I., Reversade, B., Zakin, L., De Robertis, E.M., 2001. Proteolytic cleavage of Chordin as a switch for the dual activities of Twisted gastrulation in BMP signaling. *Development* 128, 4439–4447.
- Lawson, K.A., Dunn, N.R., Roelen, B.A., Zeinstra, L.M., Davis, A.M., Wright, C.V., Korving, J.P., Hogan, B.L., 1999. Bmp4 is required for the generation of primordial germ cells in the mouse embryo. *Genes Dev.* 13, 424–436.
- Le Mouellic, H., Lallemand, Y., Brulet, P., 1990. Targeted replacement of the homeobox gene Hox-3.1 by the *Escherichia coli* lacZ in mouse chimeric embryos. *PNAS* 87, 4712–4716.
- Little, S.C., Mullins, M.C., 2006. Extracellular modulation of BMP activity in patterning the dorsoventral axis. *Birth Defects Res. C. Embryo Today* 78, 224–242.
- Luo, G., Hofmann, C., Bronckers, A.L., Sohocki, M., Bradley, A., Karsenty, G., 1995. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. *Genes Dev.* 9, 2808–2820.
- Massague, J., Chen, Y.G., 2000. Controlling TGF-beta signaling. *Genes Dev.* 14, 627–644.
- Moser, M., Binder, O., Wu, Y., Aitsebaomo, J., Ren, R., Bode, C., Bautch, V.L., Conlon, F.L., Patterson, C., 2003. BMPER, a novel endothelial cell precursor-derived protein, antagonizes bone morphogenetic protein signaling and endothelial cell differentiation. *Mol. Cell. Biol.* 23, 5664–5679.
- Moser, M., Yu, Q., Bode, C., Xiong, J.W., Patterson, C., 2007. BMPER is a conserved regulator of hematopoietic and vascular development in zebrafish. *J. Mol. Cell. Cardiol.* 43, 243–253.
- Nakayama, N., Han, C.E., Scully, S., Nishinakamura, R., He, C., Zeni, L., Yamane, H., Chang, D., Yu, D., Yokota, T., Wen, D., 2001. A novel chordin-like protein inhibitor for bone morphogenetic proteins expressed preferentially in mesenchymal cell lineages. *Dev. Biol.* 232, 372–387.
- Nakayama, N., Han, C.Y., Cam, L., Lee, J.I., Pretorius, J., Fisher, S., Rosenfeld, R., Scully, S., Nishinakamura, R., Duryea, D., Van, G., Bolon, B., Yokota, T., Zhang, K., 2004. A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage. *Development* 131, 229–240.
- Nosaka, T., Morita, S., Kitamura, H., Nakajima, H., Shibata, F., Morikawa, Y., Kataoka, Y., Ebihara, Y., Kawashima, T., Itoh, T., Ozaki, K., Senba, E., Tsuji, K., Makishima, F., Yoshida, N., Kitamura, T., 2003. Mammalian twisted gastrulation is essential for skeleto-lymphogenesis. *Mol. Cell. Biol.* 23, 2969–2980.
- O'Connor, M.B., Umulis, D., Othmer, H.G., Blair, S.S., 2006. Shaping BMP morphogen gradients in the *Drosophila* embryo and pupal wing. *Development* 133, 183–193.
- Oelgeschlager, M., Larrain, J., Geissert, D., De Robertis, E.M., 2000. The evolutionarily conserved BMP-binding protein Twisted gastrulation promotes BMP signalling. *Nature* 405, 757–763.
- Petryk, A., Anderson, R.M., Jarcho, M.P., Leaf, I., Carlson, C.S., Klingensmith, J., Shawlot, W., O'Connor, M.B., 2004. The mammalian twisted gastrulation gene functions in foregut and craniofacial development. *Dev. Biol.* 267, 374–386.
- Piccolo, S., Agius, E., Lu, B., Goodman, S., Dale, L., De Robertis, E.M., 1997. Cleavage of Chordin by Xoloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity. *Cell* 91, 407–416.
- Ralston, A., Blair, S.S., 2005. Long-range Dpp signaling is regulated to restrict BMP signaling to a crossvein competent zone. *Dev. Biol.* 280, 187–200.
- Rentzsch, F., Zhang, J., Kramer, C., Sebald, W., Hammerschmidt, M., 2006. Crossveinless 2 is an essential positive feedback regulator of Bmp signaling during zebrafish gastrulation. *Development* 133, 801–811.
- Scott, I.C., Blitz, I.L., Pappano, W.N., Imamura, Y., Clark, T.G., Steiglit, B.M., Thomas, C.L., Maas, S.A., Takahara, K., Cho, K.W., Greenspan, D.S., 1999. Mammalian BMP-1/Tolloid-related metalloproteinases, including novel family member mammalian Tolloid-like 2, have differential enzymatic activities and distributions of expression relevant to patterning and skeletogenesis. *Dev. Biol.* 213, 283–300.
- Scott, I.C., Blitz, I.L., Pappano, W.N., Maas, S.A., Cho, K.W., Greenspan, D.S., 2001. Homologues of Twisted gastrulation are extracellular cofactors in antagonism of BMP signalling. *Nature* 410, 475–478.
- Serpe, M., Umulis, D., Ralston, A., Chen, J., Olson, D.J., Avanesov, A., Othmer, H., O'Connor, M.B., Blair, S.S., 2008. The BMP binding protein Crossveinless 2 is a short-range, concentration-dependant, biphasic modulator of BMP signaling in *Drosophila*. *Dev. Cell.* 14, 940–953.
- Shimmi, O., Ralston, A., Blair, S.S., O'Connor, M.B., 2005. The crossveinless gene encodes a new member of the Twisted gastrulation family of BMP-binding proteins which, with Short gastrulation, promotes BMP signaling in the crossveins of the *Drosophila* wing. *Dev. Biol.* 282, 70–83.
- Suzuki, N., Labosky, P.A., Furuta, Y., Hargett, L., Dunn, R., Fogo, A.B., Takahara, K., Peters, D.M., Greenspan, D.S., Hogan, B.L., 1996. Failure of ventral body wall closure in mouse embryos lacking a procollagen C-proteinase encoded by Bmp1, a mammalian gene related to *Drosophila* tolloid. *Development* 122, 3587–3595.
- Vilmos, P., Sousa-Neves, R., Lukacsovich, T., Marsh, J.L., 2005. crossveinless defines a new family of Twisted-gastrulation-like modulators of bone morphogenetic protein signalling. *EMBO Rep.* 6, 262–267.
- Wang, Y.C., Ferguson, E.L., 2005. Spatial bistability of Dpp-receptor interactions during *Drosophila* dorsal-ventral patterning. *Nature* 434, 229–234.
- Zakin, L., De Robertis, E.M., 2004. Inactivation of mouse Twisted gastrulation reveals its role in promoting Bmp4 activity during forebrain development. *Development* 131, 413–424.
- Zhang, J.L., Huang, Y., Qiu, L.Y., Nickel, J., Sebald, W., 2007. von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms. *J. Biol. Chem.* 282, 20002–20014.
- Zhang, Z.L., Qiu, L.Y., Katsch, A., Weidauer, S., Patterson, L., Hammerschmidt, M., Sebald, W., Mueller, T.D., 2008. Crystal Structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding. *Dev. Cell.* 5, 739–750.
- Zhao, M., Harris, S.E., Horn, D., Geng, Z., Nishimura, R., Mundy, G.R., Chen, D., 2002. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. *J. Cell. Biol.* 157, 1049–1060.

Supplementary Table 1

**Genotypes of embryos obtained from  $Cv2^{+/-};Chd^{+/-}$  intercrosses  
between 15.5 and 17.5 d.p.c. †**

Genotype	Number of embryos	Observed percentage (Expected percentage)
$Cv2^{+/+};Chd^{+/+}$	13	8.2 (6.25)
$Cv2^{+/-};Chd^{+/+}$	14	8.8 (12.5)
$Cv2^{+/+};Chd^{+/-}$	23	14.5 (12.5)
$Cv2^{+/-};Chd^{+/-}$	43	27.0 (25)
$Cv2^{+/+};Chd^{-/-}$	7	4.4 (6.25)
$Cv2^{+/-};Chd^{-/-}$	15	9.4 (12.5)
$Cv2^{-/-};Chd^{+/-}$	24	15.1 (12.5)
$Cv2^{-/-};Chd^{+/+}$	10	6.3 (6.25)
$Cv2^{-/-};Chd^{-/-}$	10	6.3 (6.25)
Total	159	

† Crosses were performed in the B6SJLF1/J genetic background. Embryos were harvested before term to avoid mothers eating their defective pups.

\* Statistical analysis indicates that differences found between observed percentages and expected percentages were not significant (chi-square test).


Supplementary Table 2

<b>Influence of <i>Chd</i> dosage on the lumbar neural arch phenotype of <i>Cv2</i><sup>-/-</sup> embryos<sup>†</sup></b>				
Genotype	Number of embryos	Strongest phenotype <sup>‡</sup>	Intermediate phenotype	Weakest phenotype
<i>Cv2</i> <sup>-/-</sup> ; <i>Chd</i> <sup>+/+</sup>	10	8	2	0
<i>Cv2</i> <sup>-/-</sup> ; <i>Chd</i> <sup>+/-</sup>	16	3	10	3
<i>Cv2</i> <sup>-/-</sup> ; <i>Chd</i> <sup>-/-</sup>	5	0	2	3
Total	31 embryos from 9 independent litters*			

<sup>†</sup> Crosses were performed in the B6SJLF1/J genetic background. Embryos were harvested before term to avoid mothers eating their defective pups.

<sup>‡</sup> The phenotype of the lumbar neural arches was compared between littermates. Within one litter genotypes were ordered according to an arbitrary three point scale, strongest, intermediate and weakest, where strongest means that the neural arches were the most affected, and intermediate and weakest less affected respectively. The rescue of the lumbar neural arches, although mild, was found to be statistically significant using a chi-square test for independence ( $p < 0.002$ ).

\* All other *Cv2*<sup>-/-</sup> phenotypes were unaffected by the dose of *Chd* and conversely the *Chd* mutant phenotype was unaffected by *Cv2* dosage.



**Supplementary Fig. 1. Targeted inactivation and expression pattern of the Cv2 gene.**

(A) Schematic representation of the wild-type and mutant alleles of the Cv2 gene.

Black boxes indicate exons. The Cv2-5'2 and Cv2-3'2 PCR primers used to screen for homologous recombination are indicated.

(B) Southern blot analysis of the 3' region of the Cv2 gene.


The Cv2 3' probe (700 bp SacII-BglII fragment) detects a wild-type (wt) band of 11 kb and a mutant band (ko) of 7 kb on genomic DNAs digested with BamHI (E).

(C) PCR genotyping of the mouse Cv2 mutant strain.


The Cv2up and Cv2down primers amplify a wild-type band of 540 bp and the pGN1 and Cv2down primers amplify a mutant band of 454 bp.

(D) RT-PCR analysis of mRNAs extracted from wild-type and mutant mouse embryonic fibroblasts (MEFs), showing the absence of the Cv2 transcript and the presence of the LacZ reporter transcript in mutant cells. HPRT is used as a loading control.

(E-F, E'-F') Comparison of the Cv2 expression pattern by in situ hybridization and  $\beta$ -galactosidase activity. (E, F) Cv2 is expressed in tail bud (tb), dorsal neural tube (dnt) and brain dorsal midline (dm); these are all areas of high BMP signaling. Cv2 transcripts are additionally found in branchial arches (ba) and heart (h) at 9.5 d.p.c. (E', F') The LacZ transgene faithfully mimics the Cv2 expression pattern, except for the staining in the heart which appeared stronger by  $\beta$ -galactosidase staining perhaps because of a greater stability of the enzyme compared to the Cv2 transcript. Inset in F' shows the brain dm expression in a frontal view.



**Supplementary Fig. 2.** Skeletal phenotypes of *Cv2*<sup>-/-</sup> neonates. Bone was stained with Alizarin Red and cartilage with Alcian Blue. Skeletons and skulls of wild-type (A, B) and *Cv2*<sup>-/-</sup> (A', B') neonates. Note in *Cv2*<sup>-/-</sup> the dramatic reduction of the neural arches (na) and ossification centers (oc) (compare A to A'), the reduced ossification of the tympanic ring (ty) (white arrowhead) and the defective fusion of the basisphenoid bone (bs) (white asterisk) (compare B to B'). bo, basioccipital bone, ot, otic capsule, pl, palatine, ps, presphenoid. (C, C') *Cv2*<sup>-/-</sup> phenotype in the thoracic and lumbar regions. In the mutant, a posterior homeotic transformation of the 13th vertebra characterized by the absence of the 13th rib (black asterisk in C'), is observed. L1, first lumbar vertebra; R12, 12th rib; R13, 13th rib; T12, 12th thoracic vertebra; T13, 13th thoracic vertebra. (D, D') The tail in the *Cv2*<sup>-/-</sup> is shorter than wild-type due to the reduced size of its vertebral bodies.



### Supplementary Figure 3

Effect of recombinant Chd, CV2 and Tsg proteins on the phosphorylation of Smad1 by BMP4, in *Cv2<sup>-/-</sup>;Tsg<sup>-/-</sup>* double mutant MEFs. Top and middle panels show signals obtained with the pSmad1 and αTubulin antibodies respectively. αTubulin is used as a loading control.

Bottom panel corresponds to the merged images obtained using the Li-Cor Odyssey infrared imager where green corresponds to the pSmad1 signal and red to that of αTubulin used as a loading control. As previously shown in this manuscript, CV2 inhibited BMP4 signaling, compare lane 2 to 4,

while Chd or Tsg at 1 nM did not affect pSmad1 levels significantly, compare lane 2 to 3 and 5. The inhibitory effect of Chd became apparent in the presence of Tsg, compare lane 3 to 8, presumably through the formation of a Tsg/BMP/Chd ternary complex, as described in the literature (Larrain et al., 2001).

As described in Figure 7, when CV2 was incubated together with Tsg the inhibition of pSmad1 was more efficient, compare lane 4 to 6, indicating a cooperation between CV2 and Tsg activities.

This is in agreement with the existence of CV2/Tsg/BMP4 ternary complexes (Ambrosio et al., 2008). Interestingly, when CV2 and Chd were both present this inhibition was stronger than CV2 or Chd alone, compare lane 7 to 4 and 6. This indicates potent anti-BMP effects of CV2 in combination with Chd.

Finally, when all the components (Tsg, CV2 and Chd) were present, the overall effect was a strong reduction of pSmad1 levels, compare lane 9 to 2. This inhibition was comparable to that obtained when CV2 was incubated together with Chd, compare lane 9 to 7. In conclusion, the immediate effect of addition of Chd, CV2 and Tsg is to inhibit BMP signaling in *Cv2<sup>-/-</sup>;Tsg<sup>-/-</sup>* MEFs.